Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lunai BioworksLNAI +1.40%17 Debt-to-Equity is -0.15 as of Mar. 2026. GuruFocus rates LNAI with a GF Score™ of 17/100. The stock has 5 warning signs investors should review. Among 966 Biotechnology companies, Lunai Bioworks ranks worse than 103519.57% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Lunai Bioworks's Debt-to-Equity or its related term are showing as below:
LNAI'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.55 Med: 0.05 Max: 1.36
Current: -0.15
During the past 13 years, the highest Debt-to-Equity Ratio of Lunai Bioworks was 1.36. The lowest was -0.55. And the median was 0.05.
LNAI's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.15
vs LNAI: -0.15
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Lunai Bioworks Debt-to-Equity Related Terms
Lunai Bioworks Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Lunai Bioworks's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LNAI vs AZTR, GDTC, APRE: Debt-to-Equity Comparison
For the Biotechnology subindustry, Lunai Bioworks's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lunai Bioworks Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lunai Bioworks's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Lunai Bioworks's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lunai Bioworks (LNAI) has a Debt-to-Equity of -0.15 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Lunai Bioworks and its competitors. According to the industry distribution chart, Lunai Bioworks ranks #999999 out of 966 companies in the Biotechnology industry.
Is Lunai Bioworks' Debt-to-Equity too high?
Lunai Bioworks' current Debt-to-Equity is -0.15. Based on the distribution chart, Lunai Bioworks ranks #999999 out of 966 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lunai Bioworks has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Lunai Bioworks' Debt-to-Equity compare to AZTR and GDTC?
According to the Biotechnology industry distribution chart, Lunai Bioworks ranks #999999 out of 966 companies for Debt-to-Equity. This places Lunai Bioworks in the lower half of its industry. The industry median Debt-to-Equity is 0.15. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.15, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Lunai Bioworks and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lunai Bioworks's current Debt-to-Equity is -0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lunai Bioworks stock overvalued right now?
Lunai Bioworks (LNAI) has a current Debt-to-Equity of -0.15. The current Debt-to-Equity is -0.15. Lunai Bioworks' overall GF Score™ is 17/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Lunai Bioworks (LNAI), the current Debt-to-Equity is -0.15 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.
17GF Score
Get the complete analysis for LNAI
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LNAI has been successfully added to your 
